

Practitioner's Docket No. MWH-0425US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent application of Chew, Anne et al.,
for Haplotypes of the ICAM2 Gene

Assistant Commissioner for Patents
Washington, D.C. 20231


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF FILING OR
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. section 1.97(b))

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

Date: 11/14/01

Reg. No. 47,562
Tel. No.: 203-786-3473
Customer No.: 25106


Gisela M. Field
Genaissance Pharmaceuticals, Inc.
5 Science Park
New Haven, CT 06511

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2of 2

Complete if Known

Application Number

Filing Date

First Named Inventor

Group Art Unit

Examiner Name

Attorney Docket Number

11/08/2001

Anne Chew

1632

Joseph T. Woita

MWH-0425US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BA	AKELLA AND HALL, "Expression of the adhesion molecules ICAM-1 and ICAM-2 on tumor cell lines...", Eur. J. Imm., Vol. 22 (No. 4), p. 1069-1074, (April 1992).	
	BB	BUETOW, K.H. ET AL., "Reliable identification of large numbers of candidate SNPs from public EST data," Nature Genetics, Vol. 21 (No. 3), p. 323-325, (March 1999).	
	BC	BUTINI ET AL., "Intercellular adhesion molecules (ICAM)-1 ICAM-2 and ICAM-3 function as counter-receptors for lymphocyte function-associated molecule 1 in human immunodeficiency virus-mediated syncytia formation," European Journal of Immunology, Vol. 24 (No. 9), p. 2191-2195, (September 1994).	
	BD	GALEA ET AL., "Circulating cell adhesion molecules in HIV1-infected patients as indicator markers for AIDS progression," Res Immunol, Vol. 148 (No. 2), p. 109-117, (February 1997).	
	BE	GERWIN, N. ET AL., "Prolonged Eosinophil Accumulation in Allergic Lung Interstitium of ICAM-2 Deficient Mice Results in Extended Hyperresponsiveness," Immunity, Vol. 10, p. 9-19, (January 1999).	
	BF	KURAMOTO ET AL., "The alymphoplasia (aly) mutation co-segregates with the intercellular adhesion molecule-2 (ICAM-2) on mouse chromosome 11," International Immunology, Vol. 6 (No. 7), p. 991-994, (July 1994).	
	BG	MCLAUGHLIN ET AL., "Characterisation of the tumour necrosis factor (TNF)-a response elements in the human ICAM-2 promoter," Journal of Cell Science, Vol. 112, p. 4695-4703, (1999).	
	BH	SIMMONS ET AL., "The Role of ICAM Expression in Immunity and Disease," Cancer Surveys, Vol. 24, p. 141-155, (1995).	
	BI	STAUNTON ET AL., "Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1," Nature, Vol. 339, p: 61-64, (1989).	
	BJ	SULTAN ET AL., "Sporozites of Plamdoium yoelii infect mice with targeted deletions in ICAM-1 and ICAM-2 or complement components C3 and C4," Molecular and Biochemical Parasitology, Vol. 88, p. 263-266, (1997).	

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.